ArticleCellular & molecular immunology2013
Immune regulation by CD52-expressing CD4 T cells.
Article in Cellular & molecular immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.NPJ breast cancer · 2026Article
- Randomized Spatial PCA (RASP): A computationally efficient method for dimensionality reduction of high-resolution spatial transcriptomics data.PLoS computational biology · 2025Article
- Single cell analysis identifies distinct CD4 + T cells associated with the pathobiology of pediatric obesity related asthma.Scientific reports · 2025Article
- Engineering antigen-presenting cells for immunotherapy of autoimmunity.Advanced drug delivery reviews · 2024Review
- Glycosylation in the tumor immune response: the bitter side of sweetness.Acta biochimica et biophysica Sinica · 2024Review
- Article
- Identification of potential diagnostic biomarkers of atherosclerosis based on bioinformatics strategy.BMC medical genomics · 2023Article
- Article
- Long-Term Elevated Siglec-10 in Cerebral Spinal Fluid Heralds Better Prognosis for Patients with Aneurysmal Subarachnoid Hemorrhage.Disease markers · 2022Article
- Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.Journal of personalized medicine · 2021Review
- High expression of CD52 in adipocytes: a potential therapeutic target for obesity with type 2 diabetes.Aging · 2021Article
- A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma.Translational lung cancer research · 2021Article
- Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.ImmunoTargets and therapy · 2021Review
- Multiregion single-cell sequencing reveals the transcriptional landscape of the immune microenvironment of colorectal cancer.Clinical and translational medicine · 2021Article
- CD52+ regulatory T cells and CD52-expressing sperms downregulated in couples with unexplained infertility: A case-control study.International journal of reproductive biomedicine · 2020Article
- Immune reconstitution, glomerulonephritis, and successful treatment with rituximab.Clinical nephrology. Case studies · 2020Article
- Impact of Immune-Modulatory Drugs on Regulatory T Cell.Transplantation · 2016Review
- Establishment a CHO Cell Line Expressing Human CD52 Molecule.Reports of biochemistry & molecular biology · 2016Article
- Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell regulation by CD52-expressing CD4 T cells appears to operate by two different and possibly synergistic mechanisms. The first is by its release from the cell surface of CD4 T cells that express high levels of CD52 that then binds to the inhibitory sialic acid-binding immunoglobulin-like lectins-10 (Siglec-10) receptor to attenuate effector T-cell activation by impairing phosphorylation of T-cell receptor associated lck and zap-70. The second mechanism appears to be by crosslinkage of the CD52 molecules by an as yet unidentified endogenous ligand that is mimicked by a bivalent anti-CD52 antibody that results in their expansion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.